Previous close | 2.7800 |
Open | 2.7600 |
Bid | 0.0000 x 1100 |
Ask | 0.0000 x 900 |
Day's range | 2.4000 - 2.8500 |
52-week range | 1.2500 - 4.0800 |
Volume | |
Avg. volume | 21,134 |
Market cap | 20.919M |
Beta (5Y monthly) | 1.27 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.3500 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.00 |
Following evidence of marked pharmacodynamic activity in first cohort, Cohort 2 has dose reduced while anticipating a similar effectNEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to receive a single dose of Decoy20 in the INDP-D101 trial. This cohort dose is a dose reduction from the previous cohort based on the significant pharmacodynamic effect seen with
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is being held on September 11 – 13, 2023 at the Lotte New York Palace Hotel. Presentation Date:September 13, 2023 Time:8:30am ET Webcast Link: https://journey.ct.events/view/a2bb617e-99c0-4e6c-8b4a-15d80a10a66f A live webcast of the
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...